Abstract. Bombesin (BN) analogs bind with high affinity to gastrin-releasing peptide receptors (GRPRs) that are upregulated in prostate cancer and can be used for the visualization of prostate cancer. The aim of this study was to investigate the influence of radionuclide-chelator complexes on the biodistribution pattern of the $^{111}$In-labeled bombesin antagonist PEG$_2$-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH$_2$ (PEG2-RM26) and to identify an optimal construct for SPECT imaging. A series of RM26 analogs N-terminally conjugated with NOTA, NODAGA, DOTA and DOTAGA via a PEG$_2$ spacer were radiolabeled with $^{111}$In and evaluated both in vitro and in vivo. The conjugates were successfully labeled with $^{111}$In with 100% purity and retained binding specificity to GRPR and high stability. The cellular processing of all compounds was characterized by slow internalization. The IC$_{50}$ values were in the low nanomolar range, with lower IC$_{50}$ values for positively charged natIn-NOTA-PEG$_2$-RM26 (2.6±0.1 nM) and higher values for negatively charged natIn-DOTAGA-PEG$_2$-RM26 (4.8±0.5 nM). The kinetic binding studies showed K$_D$ values in the picomolar range that followed the same pattern as the IC$_{50}$ data. The biodistribution of all compounds was studied in BALB/c nu/nu mice bearing PC-3 prostate cancer xenografts. Tumor targeting and biodistribution studies displayed rapid clearance of radioactivity from the blood and normal organs via kidney excretion. All conjugates showed similar uptake in tumors at 4 h p.i. The radioactivity accumulation in GRPR-expressing organs was significantly lower for DOTA- and DOTAGA-containing constructs compared to those containing NOTA and NODAGA. $^{111}$In-NOTA-PEG$_2$-RM26 with a positively charged complex showed the highest initial uptake and the slowest clearance of radioactivity from the liver. At 4 h p.i., DOTA- and DOTAGA-coupled analogs showed significantly higher tumor-to-organ ratios compared to NOTA- and NODAGA-containing variants. The NODAGA conjugate demonstrated the best retention of radioactivity in tumors, and, at 24 h p.i., had the highest contrast to blood, muscle and bones.

Introduction

Bombesin analogs, which show significant potential in the diagnosis and therapy of prostate cancer, have been widely investigated in recent years. The attractiveness of these peptides is determined by their ability to bind selectively and avidly to gastrin-releasing peptide receptors (GRPRs), which are ectopically expressed in several tumors, including prostate and breast cancer (1). Imaging of GRPR expression in prostate cancer using high-affinity radiolabeled bombesin analogs could therefore complement the current prostate-specific antigen (PSA)-based screening methods, which have limited standalone diagnostic specificity and can generate false positive and false negative results (2). This type of imaging could also provide an answer to the discrepancy between the histological prevalence and clinical disease encountered in biopsies (3). Moreover, it could allow preoperative assessment of lymph node involvement and other metastases, which are crucial preconditions for adequate staging and treatment selection (4). However, the detection of subcentimeter metastases is challenging and requires imaging solutions that are characterized by high sensitivity (5).
The potential benefit of radionuclide molecular imaging using peptide-based targeting vectors is supported by the success reported for somatostatin analogs, which also paved the way for the design and development of several bombesin derivatives in the last decade. While the initial consensus was that internalization of the receptor-ligand complex is a decisive precondition for optimal imaging and therapy (6), the superior results obtained using somatostatin antagonists (7) led to a paradigm shift in bombesin analog development, from agonists to antagonists. The study by Cescato and co-workers showed that bombesin-based antagonists had superior tumor targeting and pharmacokinetic characteristics compared to agonists without eliciting a physiological response (8).

Recently, we have investigated a high-affinity antagonistic analog of bombesin [RM26, (D-Phe6, Stal3, Leu14)-bombesin(6-14)] conjugated to a 1,4,7-triazaacyclononane-N, N',N''-triacetic acid (NOTA) chelator via a diethylene glycol (PEG2) spacer (NOTA-PEG2-RM26). This construct was labeled with 68Ga, 111In and Au19F and showed favorable pharmacokinetic properties (9,10). The high affinity to GRPR (Kd in the picomolar range) suggested that no further modifications of the peptide sequence are required (9). Nonetheless, several other parameters known to influence the targeting and biodistribution properties of radiopeptides could be employed to obtain higher sensitivity and specificity (11). Such parameters include overall and local distribution of charge and lipophilic patches and can be tuned by modifications to the spacers, chelating moieties and radionuclides.

Therefore, in a further attempt to optimize the biodistribution profile for possible clinical use, several modifications in the length of spacers and different chelating agents have been explored. The effects of the length of PEG spacers as hydrophilicity modifiers (NOTA-PEG2-RM26, n=2,3,4,6) were shown to be minor (12). However, the use of different macrocyclic chelators for the labeling of RM26 with 68Ga had a profound influence on the biodistribution profile of bombesin analogs, appreciably altering the blood clearance, tumor uptake and kidney retention of radioactivity (13). In this regard, the constructs containing the triaza chelators NOTA and 1,4,7-triazaacyclononane-1-glutaric acid-4,7-acetic acid (NODAGA), namely 68Ga-NOTA-PEG2-RM26 and 68Ga-NODAGA-PEG2-RM26 provided better imaging properties (higher tumor-to-organ ratios) compared to 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7,10-tetraazacyclodecane-1-(glutaric acid)-4,7,10-triacetic acid (DOTAGA) coupled analogs. The higher tumor uptake and faster clearance from blood and healthy tissues indicated that NOTA is the superior chelator for 68Ga labeling of RM26 (NOTA > NODAGA > DOTA > DOTAGA) for imaging of prostate cancer using positron emission tomography (PET) (13).

To date, despite its value as a high-end diagnostic tool, PET imaging is limited by the large infrastructure required for the production of β+ emitting radioisotopes and the higher cost of imaging equipment, making PET an expensive technology (14). Single-photon emission computed tomography (SPECT) cameras, on the other hand, are more widely available, and there is a broader array of available and less-expensive SPECT radiotracers compared to PET tracers. Moreover, SPECT radionuclides have a longer half-life, which allows for imaging at later time points when better contrast can be achieved. Additionally, SPECT radionuclides can be transported to distant hospitals and imaging centers. One commonly used SPECT radionuclide in clinical context is 111In (2.8 days half-life).

Different radionuclides have also been known to impact the behavior of radiopharmaceuticals (15,16). It is increasingly evident that the influence of radionuclides is intimately connected to the chelator moiety. Therefore, matching the isotopes and chelators could substantially improve the pharmacokinetic properties of radiotracers (17). A good match depends on a multitude of factors, including the coordination number of the metal ion, chelator denticity, radionuclide-chelator complex geometry, oxidation state of the metal ion, and the rate of complex formation and dissociation (18).

The aim of the current study was to evaluate the influence of the radionuclide-chelator complex on the biodistribution and targeting properties of 111In-labeled bombesin antagonist RM26 and to identify an optimal construct for SPECT imaging of GRPR expression. For this purpose, four different constructs containing NOTA, NODAGA, DOTA and DOTAGA macrocyclic chelators [further denoted as X-PEG2-RM26, X=NOTA, NODAGA, DOTA, DOTAGA (Fig. 1)] were radiolabeled with 111In and evaluated in vitro and in vivo.

Materials and methods

Peptide synthesis. X-PEG2-RM26 (RM26= [D-Phe6, Stal3, Leu14]Bombesin[6-14], X= NOTA, DOTA, NODAGA and DOTAGA) were synthesized by manual solid-phase peptide synthesis (SPPS) using standard Fmoc/t-Bu conditions, as previously described (9,13). The identity was confirmed by HPLC/MS using a Kinetex 2.6 µm C18 (50x3.0 mm) column and a 2.5-min, 5-60% acetonitrile/water (0.05% formic acid) gradient. Purity was determined by UV-HPLC (220 nm) and was >96.5% for all conjugates (13).

Radiolabeling. All 111In labelings and quality controls were performed based on protocols developed and presented previously (9). Briefly, an aqueous solution of 10 nmol (10 µl in Milli-Q water) of X-PEG2-RM26 was buffered with 80 µl (0.2 M, pH 5.5) of ammonium acetate (Merck). The buffers for 111In labeling were purified from metal contamination using Chelex 100 resin (Bio-Rad Laboratories). After the addition of 60 MBq (80-150 µl in 0.05 M hydrochloric acid) of 111In (Covidien), the reaction mixture was incubated for 10 min at 90°C.

The yield, radiochemical purity and in vitro stability studies of 111In-X-PEG2-RM26 were analyzed using instant thin-layer chromatography (ITLC) strips (150-771 Dark Green, Tec-Control Chromatography strips from Biodex Medical Systems). Citric acid (0.2 M, pH 2.0) was used as the running buffer. In this system, free indium and its complexes migrate with the solvent front (RF=1.0), while peptides remain at the origin (RF=0.0). The system was previously cross-validated using radioHPLC and radioSDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) (9,10). To test the labeling stability, 111In-X-PEG2-RM26 was incubated for 1 h at room temperature in the presence of 1000-fold molar excess
of EDTA disodium salt (Sigma). The samples were analyzed by ITLC.

Before in vivo studies, the reaction mixtures of $^{111}$In-X-PEG$_2$-RM26 were additionally purified using solid phase extraction. Briefly, the reaction mixtures were diluted with 3 ml of deionized water and passed through a 1 ml Oasis HLB cartridge (Waters). The cartridge was then washed with 5 ml of deionized water. The radiolabeled product was eluted with 1 ml of 1:1 EtOH/water.

In vitro studies. GRPR-expressing PC-3 human prostate cancer cells (ATCC) were cultured in RPMI media complemented with 10% fetal calf serum, 2 mM L-glutamine and PEST (penicillin 100 IU/ml) (all from Biochrom AG). The cells were detached using trypsin-EDTA solution (0.05% trypsin, 0.02% EDTA in buffer; Biochrom AG). All experiments were performed in triplicate and 0.7x10^6 cells/dish were seeded two days before the experiment.

For the in vitro binding specificity study, PC-3 cells were incubated with 1 nM $^{111}$In-X-PEG$_2$-RM26 solutions for 1 h at 37°C. One set of dishes in each experiment was pre-incubated with 100-fold excess of unlabeled peptide, added 10 min before the addition of the radiolabeled compounds. After being washed once with serum-free media, cells were treated with 0.5 ml trypsin solution. Cell-associated radioactivity was measured in an automated gamma-counter (3-inch NaI(Tl) detector, 1480 Wizard, Wallac Oy) and presented as percentage from added radioactivity.

Cellular processing was performed on PC-3 cells, which were incubated with 2 nM $^{111}$In-X-PEG$_2$-RM26 at 37°C. At predetermined time points (1, 2, 4, 8, and 24 h after the start of incubation), the incubation medium was discarded, the cells were washed and the membrane-bound and internalized radioactivity was collected using the acid wash method previously described (9).

The half-inhibitory concentration (IC$_{50}$) was estimated for $^{111}$In-loaded metallopeptides by complete displacement experiments using the universal BN radioligand $^{125}$I-Tyr$^4$-BBN (Perkin Elmer) and increasing concentrations of the metallopeptides (0-1000 nM). Cell monolayers were incubated with $^{111}$In-X-PEG$_2$-RM26 in the presence of 0.1 pmol (~200,000 cpm) $^{125}$I-Tyr$^4$-BBN for 5 h at 4°C. After incubation, the cells were harvested, and cell-associated radioactivity was determined as described above. The half-maximal inhibitory concentration values were calculated by fitting the data by nonlinear regression using GraphPad Prism software (GraphPad Software Inc.).

The kinetic binding studies were performed using LigandTracer Yellow Instruments (Ridgeview Instruments AB) at room temperature, as previously described (19). Briefly, a Petri dish (Nunclon, diameter 100 mm, containing 3 ml culture medium) with PC-3 cells was attached to the rotating table of the instrument. After a 10-min baseline run, $^{111}$In-X-PEG$_2$-RM26 was added to the medium to obtain a ligand concentration of 0.3 nM, and the uptake curve was recorded for 200 min. Thereafter, the ligand concentration was increased to 10 nM, and the uptake curve was recorded for another 150 min. Then, $^{111}$In-X-PEG$_2$-RM26-containing medium was aspirated, 3 ml of fresh medium were added, and the dissociation curve was followed overnight. Interaction analysis and calculation of the equilibrium dissociation constant (K$_D$) were performed with TracerDrawer software (Ridgeview Instruments AB).

In vivo studies. All animal experiments were planned and performed according to the national legislation on the protection of laboratory animals, and the study plans were approved
by the local committee for animal research ethics. Groups of 4 mice per data point were used. The biodistribution and targeting to GRPRs of 111In-X-PEG2-RM26 were evaluated in female BALB/c nu/nu mice (weight: 21±1 g) bearing PC-3 xenografts (10^7 cells/mouse, implanted 2 weeks before the experiment). The average tumor size was 0.32±0.17 g at the time of the experiment.

To study tumor targeting, mice bearing PC-3 xenografts were intravenously injected into the tail vein with 45 pmol of 111In-X-PEG2-RM26 (30 kBq, 100 µl). The injected peptide dose was adjusted by dilution with non-labeled X-PEG2-RM26. The mice were euthanized at 4 and 24 h post-injection (p.i.) by intraperitoneal injection of a Ketalar-Rompun solution (10 mg/ml Ketalar and 1 mg/ml Rompun; 20 µl of solution per gram of body weight). Blood samples were collected by heart puncture. The organs of interest were collected and weighed, and their radioactivity content was measured in a gamma-counter. The organ uptake values were expressed as a percentage of injected dose per gram of tissue weight (% ID/g).

Small animal SPECT/CT imaging. Whole body scans of the subjects, injected with 111In-X-PEG2-RM26 (45 pmol, 300 kBq) were performed using the Triumph™ Trimodality
System (TriFoil Imaging, Inc., Northridge, CA, USA) at 4 h and 24 h p.i. The subjects were euthanized by CO$_2$ asphyxiation immediately before being placed in the camera. A computed tomography (CT) acquisition was first carried out to position the body of the animal in the camera at the following parameters: field of view (FOV), 80 mm; magnification, 1.48; one projection and 512 frames for 2.13 min. Subsequently, SPECT acquisition was performed in same position with the following parameters: FOV, 8 cm; 75A10 collimators (5 pinhole); acquisition energy window over 150-250 keV; 32 projections.

CT raw files were reconstructed by Filter Back Projection (FBP). SPECT raw data were reconstructed by FLEX SPECT software, which uses an ordered Subset Expectation Maximization (OSEM) iterative reconstruction algorithm. SPECT and CT data were fused and analyzed using PMOD v3.508 (PMOD Technologies Ltd., Zurich, Switzerland). Coronal SPECT-CT images of the scans were presented as maximum intensity projections (MIP) in RGB color scale to obtain a visual confirmation of the biodistribution results.

Statistics. Statistical analyses were performed by unpaired, two-tailed t-test using GraphPad Prism (version 4.00 for windows GraphPad Software, San Diego, CA, USA). P-values <0.05 were considered significant.

Results

Labeling chemistry. All constructs were successfully labeled with $^{111}$In, and the average yield was above 97% (Table I). Therefore, no additional purification was required for in vitro studies. Stability was evaluated in the presence of both 1000-fold molar excess of EDTA and in PBS for 1 h at room temperature, and the subsequent ITLC analysis showed stable coupling of $^{111}$In for all conjugates (Table I).

In vitro characterization. The results of binding specificity tests are presented in Fig. 2. Pre-saturation of receptors by adding a large molar excess of non-labeled peptide caused a significant ($p<1.3 \times 10^{-7}$) reduction in the radioactivity bound to GRPR-expressing PC-3 cells, demonstrating that the uptake was receptor mediated.

Data concerning cellular processing of $^{111}$In-X-PEG$_2$-RM26 by PC-3 cells are presented in Fig. 3. The rapid binding of all four conjugates to PC-3 cells was accompanied by slow internalization, reaching 33% of cell-associated radioactivity for $^{111}$In-NOTA-PEG$_2$-RM26; 25% for $^{111}$In-NODAGA-PEG$_2$-RM26; 22% for $^{111}$In-DOTA-PEG$_2$-RM26; and 27% for $^{111}$In-DOTAGA-PEG$_2$-RM26 after 24 h of incubation at 37°C. The pattern of cell-associated radioactivity over time for $^{111}$In-NODAGA-PEG$_2$-RM26 differed from the patterns observed for the other conjugates, despite the fact they were tested simultaneously. Maximum cell-associated radioactivity was reached after 8 h of incubation for all conjugates. For $^{111}$In-NODAGA-PEG$_2$-RM26, the cell-associated radioactivity decreased by 30% from the maximum at 24 h, while for the other conjugates it plateaued.

The half-maximal inhibitory concentration (IC$_{50}$) was determined for $^{111}$In-loaded analogs using $^{125}$I-Tyr$^4$-BBN as a displacement radioligand (Table II and Fig. 4). All IC$_{50}$ values were in the low nanomolar range. However, chelator-dependent
differences in affinity could be seen. The IC_{50} values of \(^{111}\)In-NOTA-PEG2-RM26 were lower for positively charged NOTA (2.6±0.1 nM), followed by neutral NODAGA and DOTA complexes (3.7±0.2 and 2.8±0.2 nM, respectively). The highest IC_{50} values (lowest affinity) were obtained for the negatively charged natIn-DOTAGA-PEG2-RM26 (4.8±0.5 nM).

The binding affinity of \(^{111}\)In-X-PEG2-RM26 to PC-3 cells was measured using LigandTracer Yellow instruments (Table II). The calculated K_D values were in the subnanomolar range and had the same pattern as the IC_{50} values, i.e., the affinity of \(^{111}\)In-NOTA-PEG2-RM26 was the highest and the affinity of \(^{111}\)In-DOTAGA-PEG2-RM26 was the lowest. It should be noted that all values were in a very narrow range.

In vivo studies. Biodistribution of radiolabeled conjugates and comparison of their in vivo tumor targeting were performed in female BALB/c nu/nu mice bearing PC-3 xenografts 4 and 24 h p.i. (Table III). Data obtained for \(^{111}\)In-NOTA-PEG2-RM26 at 24 h p.i. were in good agreement with previously published results (9). All conjugates demonstrated rapid whole body and blood clearance via kidney excretion. The rapid blood clearance indicated good stability of radiolabeled compounds toward transchelation to blood proteins. All conjugates demonstrated rapid and nearly equal uptakes in tumors 4 h p.i. However, the radioactivity retention in tumors at 24 h p.i. differed. While the average radioactivity concentration decreased by 25-30\% for the NOTA- and NODAGA-containing variants, it dropped by 40\% for the DOTAGA conjugate and by 60\% for the DOTA conjugate.

The pattern of radioactivity distribution in normal organs was different for the studied conjugates. The accumulated radioactivity in the liver and GRPR-expressing organs was significantly higher for \(^{111}\)In-NOTA-PEG2-RM26 and \(^{111}\)In-NODAGA-PEG2-RM26 compared to \(^{111}\)In-DOTA-PEG2-RM26.

### Table II. Inhibition of \(^{125}\)I-Tyr^4-BBN binding to PC-3 cells with natIn-X-PEG2-RM26 (X=NOTA, NODAGA, DOTA and DOTAGA).

<table>
<thead>
<tr>
<th>(^{111})In-X-PEG2-RM26</th>
<th>Competitive binding assay-IC(_{50}) (nM)(^a)</th>
<th>Real-time binding kinetics (LigandTracer)(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOTA</td>
<td>2.6±0.1</td>
<td>(1.7±0.7) x10^3</td>
</tr>
<tr>
<td>DOTA</td>
<td>2.8±0.2</td>
<td>(1.1±0.2) x10^3</td>
</tr>
<tr>
<td>NODAGA</td>
<td>3.7±0.2</td>
<td>(0.4±0.1) x10^3</td>
</tr>
<tr>
<td>DOTAGA</td>
<td>4.8±0.5</td>
<td>(1.4±0.1) x10^3</td>
</tr>
</tbody>
</table>

\(^a\)Data are presented as the mean values of three dishes ± SD. \(^b\)Data are presented as average ± standard deviation.

### Table III. Biodistribution of \(^{111}\)In-X-PEG2-RM26 (X=NOTA, NODAGA, DOTA, DOTAGA) in PC-3-xenografted BALB/c nu/nu mice 4 and 24 h p.i.

<table>
<thead>
<tr>
<th></th>
<th>NOTA</th>
<th>NODAGA</th>
<th>DOTA</th>
<th>DOTAGA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organ</td>
<td>4 h p.i.</td>
<td>24 h p.i.</td>
<td>4 h p.i.</td>
<td>24 h p.i.</td>
</tr>
<tr>
<td>Blood</td>
<td>0.0535±0.003</td>
<td>0.008±0.002</td>
<td>0.15±0.01</td>
<td>0.01±0.003</td>
</tr>
<tr>
<td>Lung</td>
<td>0.20±0.04</td>
<td>0.06±0.03</td>
<td>0.18±0.03</td>
<td>0.06±0.06</td>
</tr>
<tr>
<td>Liver</td>
<td>2.4±0.2</td>
<td>1.5±0.2</td>
<td>1.2±0.2</td>
<td>0.41±0.08</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.7±0.1</td>
<td>0.29±0.05</td>
<td>0.6±0.1</td>
<td>0.28±0.07</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2.2±0.2</td>
<td>0.076±0.009</td>
<td>16±2</td>
<td>0.22±0.05</td>
</tr>
<tr>
<td>Stomach</td>
<td>1.1±0.3</td>
<td>0.09±0.03</td>
<td>2.0±0.7</td>
<td>0.19±0.08</td>
</tr>
<tr>
<td>Intestines</td>
<td>1.1±0.1</td>
<td>0.09±0.01</td>
<td>2.9±0.6</td>
<td>0.10±0.3</td>
</tr>
<tr>
<td>Kidney</td>
<td>3.6±0.3</td>
<td>1.3±0.3</td>
<td>6.5±0.8</td>
<td>2.6±0.4</td>
</tr>
<tr>
<td>Tumor</td>
<td>2.5±0.9</td>
<td>1.7±0.5</td>
<td>3.6±0.8</td>
<td>2.7±0.6</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.06±0.01</td>
<td>0.02±0.005</td>
<td>0.05±0.02</td>
<td>0.06±0.03</td>
</tr>
<tr>
<td>Bone</td>
<td>0.11±0.03</td>
<td>0.07±0.02</td>
<td>0.08±0.02</td>
<td>0.04±0.02</td>
</tr>
<tr>
<td>Carcass</td>
<td>4.4±0.2</td>
<td>0.9±0.3</td>
<td>12.6±0.8</td>
<td>0.65±0.06</td>
</tr>
</tbody>
</table>

The organ uptake values are expressed as a percentage of injected dose per gram of tissue weight (% ID/g) except for carcass, for which the values are expressed as a percentage of the injected dose per sample (% ID). Significant difference (P<0.05) at the same time point: \(^a\)Conjugate significantly differs from NODAGA; \(^b\)Conjugate significantly differs from DOTA; \(^c\)Conjugate significantly differs from DOTAGA; \(^d\)Carcass includes gastrointestinal tract with contents and the remaining animal carcass.
111In-DOTAGA-PEG2-RM26. 111In-NOTA-PEG2-RM26 showed the highest initial uptake and the slowest clearance of radioactivity from the liver. 111In-DOTA-PEG2-RM26 had a significantly lower retention of radioactivity in kidneys at both 4 and 24 h p.i. In addition, DOTA- and DOTAGA-conjugates had a significantly lower radioactivity concentration in muscle and bones than the other two variants at both time points.

There was a clear chelator-dependent difference in the uptake of radioconjugates in receptor-positive organs (pancreas, stomach and small intestines) at 4 h p.i., when DOTA- and DOTAGA-containing variants showed a significantly lower uptake. At 4 h p.i., the pancreatic uptake of radioactivity was one order of magnitude higher for NOTA- and two orders higher for NODAGA-coupled analogs compared to DOTA- and DOTAGA-containing variants.

Tumor-to-organ ratios are presented in Fig. 5 and Table IV. Remarkably, DOTA- and DOTAGA-coupled analogs provided significantly higher tumor-to-lung, tumor-to-pancreas, tumor-to-stomach, tumor-to-small intestines, tumor-to-muscle and tumor-to-bone ratios compared to NOTA- and NODAGA-containing variants at 4 h p.i. The radioactivity accumulation in tumors at 4 h p.i. was exceeded only by kidney uptake in the case of 111In-DOTAGA-PEG2-RM26, and it was higher than that in all normal organs, including excretory organs, for 111In-DOTA-PEG2-RM26. The 24 h p.i. tumor-to-organ ratios were >1 for all conjugates except for the tumor-to-kidney ratios for NOTA, NODAGA and DOTAGA conjugates and

### Table IV. Tumor-to-normal-tissue ratios of 111In-X-PEG2-RM26 (X=NOTA, NODAGA, DOTA and DOTAGA) in PC-3-xenografted BALB/c nu/nu mice 4 h and 24 h p.i.

<table>
<thead>
<tr>
<th>Organ</th>
<th>NOTA 4 h p.i.</th>
<th>NOTA 24 h p.i.</th>
<th>NODAGA 4 h p.i.</th>
<th>NODAGA 24 h p.i.</th>
<th>DOTA 4 h p.i.</th>
<th>DOTA 24 h p.i.</th>
<th>DOTAGA 4 h p.i.</th>
<th>DOTAGA 24 h p.i.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>47±18</td>
<td>196±20</td>
<td>24±5</td>
<td>253±93</td>
<td>27±6</td>
<td>56±14</td>
<td>36±13</td>
<td>58±17</td>
</tr>
<tr>
<td>Lung</td>
<td>13±6</td>
<td>29±9</td>
<td>20±1</td>
<td>82±49</td>
<td>44±7</td>
<td>64±18</td>
<td>30±5</td>
<td>33±14</td>
</tr>
<tr>
<td>Liver</td>
<td>1±0.2</td>
<td>1±0.2</td>
<td>3.1±0.4</td>
<td>6.6±0.2</td>
<td>4±1</td>
<td>4±2</td>
<td>4±1</td>
<td>3.3±0.5</td>
</tr>
<tr>
<td>Spleen</td>
<td>4±1</td>
<td>6±1</td>
<td>6±1</td>
<td>10±1</td>
<td>3.1±0.6</td>
<td>4±2</td>
<td>4±2</td>
<td>2.5±0.7</td>
</tr>
<tr>
<td>Pancreas</td>
<td>1.1±0.5</td>
<td>22±6</td>
<td>0.23±0.04</td>
<td>12±2</td>
<td>18±2</td>
<td>55±17</td>
<td>21±5</td>
<td>69±13</td>
</tr>
<tr>
<td>Stomach</td>
<td>2.3±0.6</td>
<td>20±4</td>
<td>1.8±0.6</td>
<td>16±6</td>
<td>24±6</td>
<td>39±7</td>
<td>35±4</td>
<td>106±64</td>
</tr>
<tr>
<td>Small intestines</td>
<td>2±1</td>
<td>18±7</td>
<td>1.3±0.4</td>
<td>27±5</td>
<td>62.6±22</td>
<td>93±58</td>
<td>37±5</td>
<td>92±56</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.7±0.2</td>
<td>1.3±0.3</td>
<td>0.6±0.1</td>
<td>1.1±0.2</td>
<td>1.4±0.2</td>
<td>2.0±0.4</td>
<td>0.8±0.1</td>
<td>0.8±0.2</td>
</tr>
<tr>
<td>Muscle</td>
<td>42±19</td>
<td>83±30</td>
<td>86±34</td>
<td>646±408</td>
<td>212±52</td>
<td>284±126</td>
<td>228±136</td>
<td>277±252</td>
</tr>
<tr>
<td>Bone</td>
<td>23±6</td>
<td>27±8</td>
<td>43±6</td>
<td>104±92</td>
<td>65±22</td>
<td>51±25</td>
<td>80±29</td>
<td>46±12</td>
</tr>
</tbody>
</table>

Significant difference (P<0.05) at the same time point: *Conjugate significantly differs from NODAGA; †Conjugate significantly differs from DOTA; ‡Conjugate significantly differs from DOTAGA.

Figure 4. Inhibition of 125I-Tyr4-BBN binding to PC-3 cells with 111In-X-PEG2-RM26 [X=NOTA (●), NODAGA (▲), DOTA (◼) and DOTAGA (▼)]. Data are presented as the mean values of three dishes ± SD.

Figure 5. Tumor-to-normal-tissue ratios of 111In-X-PEG2-RM26 (X=NOTA, NODAGA, DOTA and DOTAGA) in PC-3 xenografted BALB/C nu/nu mice at (A) 4 h and (B) 24 h p.i.
the tumor-to-liver ratio for NOTA conjugate. The washout of radioactivity from normal organs, including receptor-positive organs, was more rapid than from tumors. The NODAGA conjugate demonstrated the highest tumor-to-blood (significantly over DOTA and DOTAGA conjugates), tumor-to-muscle, and tumor-to-bone ratios at 24 h p.i. among the tested conjugates.

Imaging studies. Fig. 6 shows the coronal gamma camera scans acquired 4 and 24 h after the i.v. injection of $^{111}$In-X-PEG$_2$-RM26 (X=NOTA, NODAGA, DOTA, DOTAGA) into mice bearing PC-3 xenografts. The maximum intensity projection (MIP) images confirmed the capacity of all radioconjugates to clearly visualize GRPR expression. The higher uptake of NOTA and NODAGA at the earlier time point in receptor-positive organs in the abdomen can also be seen in the gamma camera images. The significantly higher tumor-to-kidney ratios obtained at 4 h p.i. for $^{111}$In-DOTA-PEG$_2$-RM26 resulted in superior images, where only the tumor uptake was visualized. At 24 h p.i., signals from tumors in all studied conjugates dominated, while traces of radioactivity accumulation were visible in the kidneys for all conjugates except the DOTA-containing one.

Discussion

We have recently reported the influence of chelating moieties on the pharmacokinetic properties of $^{68}$Ga-labeled bombesin antagonist RM26 (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH$_2$) (13). The four constructs, which differed only in the chelating moieties ($^{68}$Ga-X-PEG$_2$-RM26, X=NOTA, NODAGA, DOTA, DOTAGA), showed significantly different biodistribution profiles, where $^{68}$Ga-NOTA-PEG$_2$-RM26 was the most promising agent for PET imaging in terms of tumor uptake, blood and whole body clearance, level of renal reabsorption of radioactivity, and tumor-to-nontumor ratios.

Despite the significant progress in the clinical application of PET during last decade, SPECT is still used for over 75% of all nuclear imaging procedures. Taking into account new developments in SPECT/CT, the number of established SPECT cameras and the low price of SPECT relative to PET, the development of SPECT tracers remains relevant. The above-mentioned conjugates (X-PEG$_2$-RM26, X=NOTA, NODAGA, DOTA, DOTAGA) could be easily labeled with indium-111, a three-valent radiometal suitable for SPECT. An additional advantage of $^{111}$In is its longer half-life (2.8 days), which allows for imaging investigations at later time points (up to 2-3 days after administration). The investigations at later time points could potentially increase sensitivity due to the clearance of non-bound radioactivity from blood and healthy tissues. For prostate cancer, the detection of low abdominal lymph node involvement, when the enlargement could not be detected by CT or magnetic resonance tomography (MRT), is an ultimate goal for nuclear imaging. It was demonstrated that for secure SPECT detection of lesions with a diameter of 8 mm, an effective uptake ratio of 84 is required (20).

At the same time, it is known that changing the radiometal could dramatically influence the affinity and biodistribution profile, leading to altered imaging properties even when radiometals have the same valency (21). Ga$^{3+}$-DOTATOC had a 5-fold higher affinity to somatostatin receptor type 2 (SSTR2) and a 2-fold higher tumor uptake compared to Y$^{3+}$-DOTATOC (22). These pronounced differences were attributed to the different coordination geometries of Ga$^{3+}$ and Y$^{3+}$ with DOTA, which resulted in conformational differences in the D-Phe$^1$ residue (23). Indium-111 has an identical oxidation state (+III) as the previously studied gallium-68 but is different.

Figure 6. Coronal MIP images showing tracer distribution in PC-3 xenografted BALB/C nu/nu mice. The animals used for SPECT camera imaging were injected with 45 pmol of $^{111}$In-X-PEG$_2$-RM26, (X=NOTA, NODAGA, DOTA and DOTAGA) (300 kBq) and euthanized at (A) 4 h and (B) 24 h p.i.
radioactivity was predominantly via kidney ultrafiltration. non-GRPR-expressing organs (Table III). The excretion of NODAGA, DOTA, DOTAGA) in mice was characterized tumor-to-blood and tumor-to-muscle ratios at 24 h p.i. between 8 and 24 h of incubation (Fig. 3). It is of interest gate demonstrated a decrease of cell-associated radioactivity the internalized radioactivity fraction and the NODAGA-containing conjugate had the highest internalized radioactivity that reached 30% of cell-associated radioactivity after 24 h. The similar internalization patterns indicated that chelators had no major effect on the cellular processing of analogs, although some differences could be observed. The NOTA-containing conjugate had the highest internalized radioactivity fraction and the NODAGA-containing conjugate demonstrated a decrease of cell-associated radioactivity between 8 and 24 h of incubation (Fig. 3). It is of interest that the NODAGA-containing conjugate demonstrated the best radioactivity retention in tumors, which lead to superior tumor-to-blood and tumor-to-muscle ratios at 24 h p.i. The binding properties of 111In-X-PEG2-RM26 (X=NOTA, NODAGA, DOTA, DOTAGA) (Fig. 1) were successfully radio-labeled with 111In, had almost identical quantitative yields and maintained in vitro binding specificity to GRPR-expressing PC-3 cells (Fig. 2). The cellular processing study confirmed the antagonistic properties of all conjugates, showing low internalization that reached 30% of cell-associated radioactivity after 24 h. The similar internalization patterns indicated that chelators had no major effect on the cellular processing of analogs, although some differences could be observed. The NOTA-containing conjugate had the highest internalized radioactivity fraction and the NODAGA-containing conjugate demonstrated a decrease of cell-associated radioactivity between 8 and 24 h of incubation (Fig. 3). It is of interest that the NODAGA-containing conjugate demonstrated the best radioactivity retention in tumors, which lead to superior tumor-to-blood and tumor-to-muscle ratios at 24 h p.i.

The binding properties of 68Ga-labeled conjugates and somatostatin analogs (13,26,27). Published for gallium-68-labeled conjugates where a strong correlation between affinity and pancreatic and tumor uptake could reflect differences in off-target interactions due to different complex geometries. This could also explain the differences between the present study and the data published for gallium-68-labeled conjugates where a strong correlation between affinity and pancreatic and tumor uptake was found (13).

The higher initial uptake and slower clearance for 111In-NOTA-PEG2-RM26 in the liver is consistent with previous results, which indicated that the presence of a positive local charge at the N terminus of the peptide increases the hepatic uptake of radioactivity (21). Remarkably, the kidney retention of radioactivity was significantly lower for 111In-DOTA-PEG2-RM26 compared to the other analogs. Overall, the tumor-to-organ ratios (except for the tumor-to-blood ratio for the NOTA conjugate) were significantly higher in most organs for the conjugates containing tetrazola chelators (DOTA and DOTAGA) at 4 h p.i. 111In-DOTA-PEG2-RM26 had the best biodistribution properties at this time point (Table IV). The tumor uptake of radioactivity exceeded the uptake in anatomically relevant organs for prostate cancer (muscle, bone, intestine) and excretory organs (liver and kidneys). This was confirmed by microSPECT/CT images containing linkers together with chelators should increase the local hydrophilicity of the probe (leading to decreased hepatic uptake), and, at the same time, not disturb the lipophilic part of the probe that is responsible for receptor recognition. This study endorsed this approach. It should also be noted that the conjugates containing NODAGA and DOTA that form neutral complexes with indium-111 had a two-fold lower liver uptake compared to the NOTA conjugate. Moreover, the liver uptake of the DOTAGA-containing variant that forms a negatively charged complex with indium-111 was 6-fold lower than the one seen for the positively charged NOTA conjugate. It should be mentioned that similar differences in affinities and liver uptake were found for gallium-labeled variants (13). Taken together, we can assume that, when increasing local hydrophilicity of the probe with the aim of decreasing hepatobiliary uptake, preference should be given to neutral moieties.

The uptake in receptor-positive organs (pancreas, stomach and small intestine) was significantly higher for the NOTA- and NODAGA-containing analogs. Notably, the uptake of radioactivity in the pancreas (the most abundantly GRPR-expressing organ), was ten-fold higher for 111In-NOTA-PEG2-RM26 and 100-fold higher for 111In-NODAGA-PEG2-RM26 compared to DOTA- and DOTAGA-coupled variants at 4 h p.i. Nonetheless, tumor uptake of indium-111 labeled conjugates was nearly equal, correlating with their similar affinity values. We can speculate that the discrepancy between pancreatic and tumor uptake is due to interspecies differences between mouse and human GRPR. Maina et al reported a 13-fold difference between the binding affinities of radiolabeled bombesin analog Z-070 to human GRPR compared to mouse GRPR, whereas another bombesin analog Demobesin1 showed no difference in binding affinity to human and mouse GRPR (28). A similar uptake pattern with differences in the pancreas that did not match the tumor uptake in mice was also seen for other radiolabeled bombesin analogs (29,30). However, the fourth extracellular domain of GRPR responsible for the binding of bombesin analogs was reported to be identical for humans and mice (31). In that case, the discrepancy between pancreatic and tumor uptake could reflect differences in off-target interactions due to different complex geometries. This could also explain the differences between the present study and the data long taken place when we designed this imaging probe (9). Our rationale was that polyethylene glycol-
Research Council (Vetenskapsrådet).
Swedish Cancer Society (Cancerfonden) and the Swedish

Acknowledgements

SPECT imaging of GRPR-expressing tumors. At later time points, despite the significant differences in tumor-to-nontumor ratios (see Fig. 5 and Table IV), all conjugates provided high contrast images of GRPR-expressing tumors due to efficient clearance of radioactivity from normal organs together with a significantly slower release from the tumors (Fig. 6). Nonetheless, taking into account the above-mentioned requirement of a high tumor-to-nontumor ratio for clear detection of small lesions (20), we should note that at the later time point of 24 h p.i., the NODAGA conjugate demonstrated the superior biodistribution profile, with the highest contrast to blood and anatomically relevant organs for prostate cancer, such as muscle and bones.

In conclusion, the radionuclide-chelator complex had a profound influence on the biodistribution and targeting properties of 111In-labeled bombesin antagonist RM26 to GRPR. The net charge of the radionuclide-chelator complex influenced the binding affinity and liver uptake of the radioconjugates. The geometry of the radionuclide-chelator complex appeared to have an even more profound effect on the biodistribution profile, accounting for the 4 h p.i. superiority of tetraaza chelators for 111In-labeled radioconjugates. However, at 24 h p.i., 111In-NODAGA-PEG2-RM26 provided the best tumor-to-organ ratios for blood and organs that are anatomically relevant for prostate cancer, and it represents a suitable candidate for SPECT imaging of GRPR-expressing tumors.

References


